DCAL Dishman Carbogen Amcis Q4 FY26 results (Jan–Mar 2026) and concall
Dishman Carbogen Amcis reported a strong Q4 and full FY26, with significant revenue growth and EBITDA margin expansion driven by both CDMO and Marketable Molecules segments. Profitability saw a substantial uplift year-on-year. The company is actively pursuing debt restructuring to reduce finance costs and is optimistic about its pipeline, particularly in ADC and India tech transfers, despite some short-term margin pressures and losses in its French subsidiary. Management provided positive guidance for future revenue growth and margin improvement.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue down 34.9%, net profit up 42.9% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 93 | 97 | 106 | 63 | 60 −35% | 40 −59% | 69 −35% |
| EBITDA | 13 | 23 | 21 | 3 | 4 −69% | -4 −117% | 1 −95% |
| Net profit | 14 | -13 | -7 | 3 | -14 −200% | -23 −77% | -4 +43% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
